New drug combo aims to keep stomach cancer from coming back
NCT ID NCT07474324
Summary
This study is for people with stage 3 stomach cancer who have already had surgery to remove their tumor. It aims to see if adding a targeted drug called disitamab vedotin to standard chemotherapy (SOX) is better at preventing the cancer from returning than the standard chemo alone. The trial will enroll 124 participants and will monitor them for side effects and how long they remain cancer-free after treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GC/GEJC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital with Nanjing Medical University
RECRUITINGNanjing, Jiangsu, 210000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.